Balyasny Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Balyasny Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.05M	Buy	+3,500	New	+$1.06M	﹤0.01%	2178
2026 Q1	–	Sell	-700	Closed	-$278K	–	2847
2025 Q4	$278K	Buy	+700	New	+$310K	﹤0.01%	2757
2025 Q2	–	Sell	-2,600	Closed	-$702K	–	2765
2025 Q1	$702K	Buy	+2,600	New	+$668K	﹤0.01%	2145
2024 Q4	–	Sell	-10,600	Closed	-$2.92M	–	2691
2024 Q3	$2.92M	Buy	+10,600	New	+$2.76M	﹤0.01%	1507
2023 Q1	–	Sell	-29,100	Closed	-$6.92M	–	2602
2022 Q4	$6.92M	Hold	29,100	–	–	0.02%	889
2022 Q3	$5.83M	Buy	+29,100	New	+$5.55M	0.02%	922
2022 Q2	–	Sell	-56,000	Closed	-$9.14M	–	2714
2022 Q1	$9.14M	Sell	56,000 -42,000	-43%	-$6.4M	0.03%	728
2021 Q4	$16.6M	Buy	+98,000	New	+$18.2M	0.06%	483
2021 Q3	–	Sell	-169,000	Closed	-$28.6M	–	1901
2021 Q2	$28.6M	Buy	+169,000	New	+$24.8M	0.14%	199
2020 Q4	–	Sell	-50,000	Closed	-$7.28M	–	1287
2020 Q3	$7.28M	Sell	50,000 -55,000	-52%	-$7.82M	0.05%	488
2020 Q2	$15.6M	Buy	+105,000	New	+$14.2M	0.13%	232
2019 Q4	–	Sell	-50,000	Closed	-$4.02M	–	1143
2019 Q3	$4.02M	Buy	+50,000	New	+$3.96M	0.03%	592
2018 Q4	–	Sell	-194,000	Closed	-$18.4M	–	1362
2018 Q3	$18.4M	Buy	+194,000	New	+$19.5M	0.08%	323
2018 Q2	–	Sell	-287,500	Closed	-$34.2M	–	1755
2018 Q1	$34.2M	Buy	+287,500	New	+$37.1M	0.14%	200

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Balyasny Asset Management's ALNY Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 89,510 shares worth $26.9M. The stake represents 0.03% of the portfolio and ranks #588 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in ALNY as recently as Q4 2025.

Balyasny Asset Management first reported a position in ALNY in Q2 2015 and has held it in 25 quarters since. The position peaked at $50.4M in Q1 2023. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Balyasny Asset Management held 89,510 shares of Alnylam Pharmaceuticals worth $26.9M as of Q2 2026.
Alnylam Pharmaceuticals was a new Balyasny Asset Management position in Q2 2026.
Alnylam Pharmaceuticals made up 0.03% of Balyasny Asset Management's portfolio in Q2 2026, its #588 holding.
Balyasny Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 25 quarters since.
Balyasny Asset Management's Alnylam Pharmaceuticals position peaked at $50.4M in Q1 2023.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.